B., & Periyasamy, L
Further analyses indicated that the association was specific to non-scarring alopecia (where hair follicles remain intact, leaving the potential for regrowth) with an increased risk of 53% and 72% compared with SGLT-2 inhibitors and DPP-4 inhibitors, respectively
DXA lean mass also includes water, organs and other fat-free tissues, and the analysis involved only a small subset of the full trial
Yes, with mass spectrometry, but these are not standard
L-theanine, phosphatidylserine and pyridoxine hydrochloride sources of vitamin B6
If phase 3 results remain positive, regulatory submissions may begin in 2026, meaning orforglipron could become available in late 2026 or 2027, depending on MHRA and NICE approval timelines